IDEAYA Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
IDEAYA Biosciences, Inc. (IDYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $20.85 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $21.19, a 50.60% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $14.07, a 57.36% decline year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $33.00, a 162.53% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $12.57, a 31.62% increase year-over-year.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $14.38, a 51.95% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $29.93, a 114.09% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $13.98, a 38.42% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $10.10, a 37.23% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $20.85 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $21.19 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $14.38 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $14.18 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | $14.02 10-Q · filed 2026-08-04 | ||||
| 2025-03-31 | $14.07 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | $29.93 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | $31.05 10-Q · filed 2025-11-04 | ||||
| 2024-06-30 | $31.85 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | $33.00 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | $13.98 10-K · filed 2026-02-17 | ||||
| 2023-09-30 | $13.54 10-Q · filed 2024-11-04 | ||||
| 2023-06-30 | $13.34 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | $12.57 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $10.10 10-K · filed 2025-02-18 | ||||
| 2022-09-30 | $9.51 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | $9.43 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | $9.55 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | $16.09 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $15.95 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $15.71 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $15.59 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | $6.16 10-K · filed 2022-03-18 | ||||
| 2020-09-30 | $6.00 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $5.38 10-Q · filed 2021-08-10 | ||||
| 2020-03-31 | $5.03 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $6.73 10-K · filed 2021-03-23 | ||||
| 2019-09-30 | $7.20 10-Q · filed 2020-11-12 | $7.20 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $7.50 10-Q · filed 2020-08-12 | ||||
| 2019-03-31 | $7.50 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | $3.28 10-K · filed 2020-03-24 | ||||
| 2018-09-30 | $3.12 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | $3.11 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |